查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593762

全球骨質疏鬆症治療市場評估：依藥物類型、藥物類別、給藥途徑、通路、地區、機會、預測（2017-2031）

Osteoporosis Treatment Market Assessment, By Drug Type, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 236 Pages | 商品交期: 3-5個工作天內

價格

全球骨質疏鬆症治療市場規模預計將從 2023 年的 147.9 億美元增至 2031 年的 214.4 億美元，預計 2024-2031 年的複合年增長率為 4.75%。由於骨質疏鬆症治療帶來的疾病負擔不斷增加、人口老化以及該領域持續的藥物開發和審批活動，預計該市場將繼續增長。

骨質疏鬆症是一種骨病，其特徵是骨密度降低和骨折風險增加。治療方法包括改變生活方式（飲食、運動）、藥物（雙磷酸鹽、荷爾蒙治療、單株抗體）和補充劑（鈣、維生素等）以強化骨骼並降低骨折風險D）等。由於全球骨質疏鬆患者數量不斷增加以及骨質疏鬆患者治療選擇的改善，預計該市場將會成長。政府和其他利害關係人的多項措施進一步提高了市場成長率。近年來，將藥物治療與營養、運動等生活方式改善相結合的個人化醫療引起了人們的關注。藥物傳輸系統的創新和對新治療劑的持續研究預計將進一步推動市場成長。治療依從性和副作用等課題仍然存在，凸顯了持續對患者進行教育和支持的必要性。在人口變化以及醫學研究和技術進步的推動下，該市場預計將增長。

例如，2024 年 8 月，倫敦國家健康與照護卓越研究所 (NICE) 推薦阿巴洛帕肽作為停經後女性骨質疏鬆症的新治療選擇，這些女性骨折風險極高。該藥物由 Theramex HQ UK Limited 銷售，商品名為 Eladynos，透過促進骨形成來增加骨密度。當標準治療無反應或不耐受時，它被用作替代藥物。

本報告研究和分析了全球骨質疏鬆症治療市場，提供市場規模和預測、市場動態以及主要參與者的狀況。

目錄

第一章專案範圍與定義

第二章研究方法

第 3 章執行摘要

第四章全球骨質疏鬆治療市場展望（2017-2031）

  • 市場規模分析與預測
    • 金額
  • 市佔率分析與預測
    • 依藥物類型
    • 依藥物類別
    • 依給藥途徑
    • 按分銷管道
    • 按地區
    • 市佔率分析：按公司劃分（金額）（前 5 名公司及其他 - 2023 年）
  • 市場地圖分析（2023 年）
    • 依藥物類型
    • 依藥物類別
    • 依給藥途徑
    • 按分銷管道
    • 按地區

第五章北美骨質疏鬆症治療市場展望（2017-2031）

  • 市場規模分析與預測
    • 金額
  • 市佔率分析與預測
    • 依藥物類型
    • 依藥物類別
    • 依給藥途徑
    • 按分銷管道
    • 分享：依國家/地區
  • 每個國家市場的評估
    • 美國骨質疏鬆症治療市場前景（2017-2031）
    • 加拿大
    • 墨西哥

第六章歐洲骨質疏鬆症治療市場展望（2017-2031）

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 波蘭

第七章亞太地區骨質疏鬆症治療市場展望（2017-2031）

  • 印度
  • 中國
  • 日本
  • 澳大利亞
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章南美洲骨質疏鬆症治療市場展望（2017-2031）

  • 巴西
  • 阿根廷

第九章中東與非洲骨質疏鬆症治療市場展望（2017-2031）

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 以色列

第10章供需分析

第11章價值鏈分析

第十二章波特五力分析

第 13 章 PESTLE 分析

第14章價格分析

第 15 章市場動態

  • 市場驅動因素
  • 市場課題

第16章市場趨勢與發展

第 17 章監理架構與創新

  • 臨床試驗
  • 監理機關的核准

第十八章專利狀況

第 19 章案例研究

第20章競爭態勢

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名的公司的 SWOT 分析
  • 前10名主要企業狀況
    • Novartis AG
    • Eli Lilly and Company
    • Amgen, Inc.
    • Viatris Inc.
    • Pfizer, Inc.
    • GlaxoSmithKline plc.
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Sanofi S.A.

第21章策略建議

第22章關於我們公司，免責聲明

Product Code: MX12274

Global osteoporosis treatment market is projected to witness a CAGR of 4.75% during the forecast period 2024-2031, growing from USD 14.79 billion in 2023 to USD 21.44 billion in 2031. The osteoporosis treatment market is poised for future growth due to the increasing disease burden of osteoporosis treatment, the aging population, and ongoing drug development and approval activities in the field.

Osteoporosis is a bone disease characterized by decreased bone density and increased fracture risk. Treatment approaches include lifestyle modifications (diet, exercise), medications (bisphosphonates, hormone therapies, and monoclonal antibodies), and supplements (calcium, vitamin D) to strengthen bones and reduce fracture risk. The market for osteoporosis drugs is anticipated to thrive under the influence of rising osteoporosis cases globally and improved treatment options available for osteoporotic patients. Several initiatives from the government and other stakeholders further strengthen the growth rate in the market. Recent trends include a focus on personalized medicine, combining pharmacological treatments with lifestyle modifications like nutrition and exercise. Innovations in drug delivery systems and ongoing research into new therapeutic agents are expected to enhance market growth further. Challenges such as treatment adherence and side effects persist, underscoring the need for ongoing patient education and support. The osteoporosis treatment market is poised for growth, fueled by demographic shifts and advancements in medical research and technology.

For instance, in August 2024, the National Institute for Health and Care Excellence (NICE), London, recommended abaloparatide as a new treatment option for osteoporosis in postmenopausal women at very high fracture risk, benefiting over 14,000 individuals. This drug, marketed as Eladynos by Theramex HQ UK Limited, enhances bone density by stimulating bone formation. It serves as an alternative for those who do not respond to or tolerate standard treatments.

Rising Prevalence of Osteoporosis and Improved Treatment Options to Boost Market Demand

The major driving factor of the osteoporosis treatment market has been the increase in the incidence of the disease among the elderly. The greater recognition of the condition has led to more patients seeking effective therapy to prevent fractures and allow the bones to become healthy again. In addition, improved treatment options, such as the introduction of bisphosphonates, hormone therapies, and newer biologics, reinforce the increased demand for these products. More attention from healthcare providers and organizations toward early diagnosis and preventive care is motivating patients to seek treatment. Personalized medicine further increases the appeal of osteoporosis therapies that are treated uniquely for every patient. With the increasing number of the aging population and the related risk of osteoporosis, the treatment for osteoporosis has become a rapidly growing and potential market. With the rising emphasis on bone health, the promising area for effective and innovative osteoporotic therapy will increase even further, pointing out the clear priority for pharmaceutical companies. According to the International Osteoporosis Foundation, osteoporosis affects approximately 6.3% of men over the age of 50 and 21.2% of women over the same age range globally, and 37 million fragility fractures occur annually in osteoporosis patients aged over 55.

Government Initiatives for Osteoporosis Treatment Drive Market Growth

Government-led programs and policies support the osteoporosis treatment market growth. Public health education programs enhance awareness about disease and its risk factors. A variety of updated guidelines on routine screening that facilitate early diagnosis and timely interventions for postmenopausal women and older adults further boost the demand for treatment. Furthermore, public funding for research on the disease also pushes the discovery of novel treatments and developments in existing treatments, encouraging pharmaceutical firms to invest in this area. Coordination between government health departments and healthcare providers will be improved education and training, improving the treatment of osteoporosis, and patient compliance with treatment. Improved policies that increase reimbursement for the treatment of osteoporosis enhance access to care and encourage more patients to seek care. For instance, in July 2024, The Centers for Medicare & Medicaid Services (CMS) proposed a 2025 Physician Fee Schedule aimed at enhancing post-fracture care for the 10 million Americans with osteoporosis. This initiative, supported by various health organizations, seeks to incentivize better care and reduce the rising costs associated with osteoporotic fractures, projected to reach USD 95 billion by 2040. Key changes include new coding for fracture management and a call for public comment to improve evidence-based care access, particularly for disproportionately affected women.

Bisphosphonate Segment to Dominate Market

The bisphosphonate class of drugs is anticipated to dominate the osteoporosis treatment market because drugs like alendronate and risedronate have proven to have an established efficacy in reducing fracture risk and, therefore, are trusted by clinicians. Other bisphosphonates are also available as generic equivalents, making them more accessible and adaptable. More often, bisphosphonates are highly regulated under clinical guidelines, and therefore, their regulated use among healthcare providers is ensured. They also tend to have a more benign safety profile compared with other newer treatments, together with a longer duration of action that permits less frequent dosing, thereby improving compliance in the patient. Ongoing studies concerning their long-term effect also help to support their clinical use further and thus remain an integral part of treatment protocols.

For instance, in March 2024, Sandoz Group AG received FDA approval for two biosimilars, Jubbonti and Wyost, targeting Amgen Inc.'s denosumab, a key treatment for osteoporosis. Jubbonti will compete with Prolia, aimed at high-risk osteoporotic men and postmenopausal women, and is also indicated for glucocorticoid-induced osteoporosis. Wyost will challenge Xgeva, which is used to prevent skeletal-related events in cancer patients. Both biosimilars have interchangeable status, allowing easy substitution without prescription changes. While this development promises improved access to essential osteoporosis treatments, Sandoz has not disclosed launch dates or pricing due to ongoing patent litigation.

North America Dominates Osteoporosis Treatment Market

The North America osteoporosis treatment market is important, as the population in this market is more aged, which leads to a greater incidence of osteoporosis and related fractures. Moreover, increased awareness of the disease by healthcare providers and patients has led to increased testing, evaluation, and treatment, which has driven this burgeoning market. Advances in healthcare infrastructure in the region provide easy access to the latest medical technologies, thus making the development and distribution of effective treatments for osteoporosis easier. Insurance coverage and reimbursement policies are other key factors driving the market. Some health insurance covers osteoporosis medications for many patients, hence increasing adherence to the treatment. Regulatory agencies, like the USFDA, ensure new therapies are placed under an adequate check, ensuring more confidence in treatment safety and efficacy.

For instance, in February 2024, the USFDA added a Boxed Warning to Prolia (denosumab), indicating an increased risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD), particularly those on dialysis. This risk is heightened in patients with CKD-mineral and bone disorders. The warning aims to ensure proper patient selection and monitoring, as severe hypocalcemia can lead to serious health complications, including hospitalization and death.

Future Market Scenario (2024-2031F)

Bone-targeting nanoparticles represent a groundbreaking advancement in the treatment of osteoporosis by increasing drug delivery specifically to bone tissue. Traditional osteoporosis medications often suffer from low targeting specificity, leading to systemic toxicity and reduced efficacy. In contrast, these nanoparticles can be engineered to recognize and bind to bone tissue, ensuring that therapeutic agents are delivered precisely where needed. The nanoparticles can encapsulate various therapeutic agents, including growth factors and nucleic acids, improving their bioavailability and stability. Their small size allows for better penetration into biological barriers, while modifications can enhance their affinity for bone surfaces. For instance, lipid nanocarriers and exosomes have shown promise in delivering anti-osteoporotic agents directly to osteoblasts, promoting bone formation and inhibiting osteoclast activity. This targeted approach minimizes side effects and maximizes therapeutic outcomes, paving the way for more effective osteoporosis treatments in the future.

Key Players Landscape and Outlook

Global pharmaceutical giants like Pfizer, Inc., Novartis AG, and many more mainly dominate the market for osteoporosis treatment. The drugs used for osteoporosis include branded and generic versions, and smaller market players cater the generic equivalents. Recent market activities include regulatory approvals and recommendations, along with acquisitions.

In July 2024, Bone Health Technologies, Inc. (BHT) acquired Wellen, a Brooklyn-based company specializing in personalized exercise programs for osteoporosis in women over 50. This acquisition aims to enhance BHT's offerings by integrating Wellen's expertise with BHT's upcoming Osteoboost vibration therapy belt, set to launch in late 2024. The combined approach seeks to provide effective, non-drug solutions for osteoporosis and osteopenia, addressing a significant public health issue affecting millions globally.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Osteoporosis Treatment Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Type
      • 4.2.1.1. Generic
      • 4.2.1.2. Branded
    • 4.2.2. By Drug Class
      • 4.2.2.1. Bisphosphonate
      • 4.2.2.2. Hormone Replacement Therapy
        • 4.2.2.2.1. Parathyroid Hormone
        • 4.2.2.2.2. Calcitonin
      • 4.2.2.3. Selective Estrogen Receptor Modulator (SERM)
      • 4.2.2.4. Rank ligand Inhibitor (RANKL)
      • 4.2.2.5. Others
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Oral
      • 4.2.3.2. Parenteral
    • 4.2.4. By Distribution Channel
      • 4.2.4.1. Hospital and Clinics
      • 4.2.4.2. Retail Pharmacies
      • 4.2.4.3. Online Pharmacies
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Drug Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Route of Administration
    • 4.3.4. By Distribution Channel
    • 4.3.5. By Region

5. North America Osteoporosis Treatment Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Type
      • 5.2.1.1. Generic
      • 5.2.1.2. Branded
    • 5.2.2. By Drug Class
      • 5.2.2.1. Bisphosphonate
      • 5.2.2.2. Hormone Replacement Therapy
        • 5.2.2.2.1. Parathyroid Hormone
        • 5.2.2.2.2. Calcitonin
      • 5.2.2.3. Selective Estrogen Receptor Modulator (SERM)
      • 5.2.2.4. Rank ligand Inhibitor (RANKL)
      • 5.2.2.5. Others
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Parenteral
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital and Clinics
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Osteoporosis Treatment Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Type
          • 5.3.1.2.1.1. Generic
          • 5.3.1.2.1.2. Branded
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Bisphosphonate
          • 5.3.1.2.2.2. Hormone Replacement Therapy
          • 5.3.1.2.2.2.1. Parathyroid Hormone
          • 5.3.1.2.2.2.2. Calcitonin
          • 5.3.1.2.2.3. Selective Estrogen Receptor Modulator (SERM)
          • 5.3.1.2.2.4. Rank ligand Inhibitor (RANKL)
          • 5.3.1.2.2.5. Others
        • 5.3.1.2.3. By Route of Administration
          • 5.3.1.2.3.1. Oral
          • 5.3.1.2.3.2. Parenteral
        • 5.3.1.2.4. By Distribution Channel
          • 5.3.1.2.4.1. Hospital and Clinics
          • 5.3.1.2.4.2. Retail Pharmacies
          • 5.3.1.2.4.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Osteoporosis Treatment Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Osteoporosis Treatment Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Osteoporosis Treatment Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Osteoporosis Treatment Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Novartis AG
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Eli Lilly and Company
    • 20.3.3. Amgen, Inc.
    • 20.3.4. Viatris Inc.
    • 20.3.5. Pfizer, Inc.
    • 20.3.6. GlaxoSmithKline plc.
    • 20.3.7. AbbVie, Inc.
    • 20.3.8. Teva Pharmaceutical Industries Ltd.
    • 20.3.9. Merck & Co., Inc.
    • 20.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 3. Global Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 6. Global Osteoporosis Treatment Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 8. North America Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 9. North America Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 10. North America Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11. North America Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. North America Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 14. United States Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 15. United States Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 16. United States Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17. United States Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Canada Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Canada Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 20. Canada Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 21. Canada Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. Canada Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23. Mexico Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Mexico Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 25. Mexico Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 26. Mexico Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27. Mexico Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Europe Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Europe Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 30. Europe Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 31. Europe Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Europe Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Germany Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 36. Germany Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 37. Germany Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Germany Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. France Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. France Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 41. France Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 42. France Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. France Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44. Italy Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Italy Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 46. Italy Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 47. Italy Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48. Italy Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. United Kingdom Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. United Kingdom Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 51. United Kingdom Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 52. United Kingdom Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53. United Kingdom Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 54. Russia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 55. Russia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 56. Russia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 57. Russia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. Russia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Netherlands Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Netherlands Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 61. Netherlands Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 62. Netherlands Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. Netherlands Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Spain Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Spain Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 66. Spain Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Spain Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Spain Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Turkey Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Turkey Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 71. Turkey Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 72. Turkey Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. Turkey Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Poland Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Poland Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 76. Poland Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 77. Poland Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78. Poland Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 79. South America Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 80. South America Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 81. South America Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 82. South America Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83. South America Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. South America Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. Brazil Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 87. Brazil Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 88. Brazil Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. Brazil Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Argentina Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Argentina Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 92. Argentina Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 93. Argentina Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Argentina Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Asia-Pacific Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 97. Asia-Pacific Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 98. Asia-Pacific Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. Asia-Pacific Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. Asia-Pacific Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
  • Figure 101. India Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. India Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 103. India Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. India Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. India Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106. China Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. China Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 108. China Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 109. China Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110. China Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 111. Japan Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 112. Japan Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 113. Japan Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 114. Japan Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. Japan Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. Australia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 117. Australia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 118. Australia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 119. Australia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120. Australia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 121. Vietnam Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Vietnam Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 123. Vietnam Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 124. Vietnam Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. Vietnam Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. South Korea Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. South Korea Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 128. South Korea Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. South Korea Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. South Korea Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Indonesia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Indonesia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 133. Indonesia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 134. Indonesia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135. Indonesia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 136. Philippines Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 137. Philippines Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 138. Philippines Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 139. Philippines Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140. Philippines Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141. Middle East & Africa Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 143. Middle East & Africa Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 144. Middle East & Africa Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. Middle East & Africa Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. Middle East & Africa Osteoporosis Treatment Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 149. Saudi Arabia Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 150. Saudi Arabia Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. Saudi Arabia Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152. UAE Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 153. UAE Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 154. UAE Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 155. UAE Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156. UAE Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157. South Africa Osteoporosis Treatment Market, By Value, In USD Billion, 2017-2031F
  • Figure 158. South Africa Osteoporosis Treatment Market Share (%), By Drug Type, 2017-2031F
  • Figure 159. South Africa Osteoporosis Treatment Market Share (%), By Drug Class, 2017-2031F
  • Figure 160. South Africa Osteoporosis Treatment Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. South Africa Osteoporosis Treatment Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023